Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) Gross Profit (2018 - 2025)

Sunshine Biopharma (SBFM) has disclosed Gross Profit for 8 consecutive years, with $3.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gross Profit rose 7.24% year-over-year to $3.1 million, compared with a TTM value of $12.3 million through Sep 2025, up 21.44%, and an annual FY2024 reading of $10.7 million, up 27.95% over the prior year.
  • Gross Profit was $3.1 million for Q3 2025 at Sunshine Biopharma, down from $3.4 million in the prior quarter.
  • Across five years, Gross Profit topped out at $3.4 million in Q2 2025 and bottomed at $21538.0 in Q1 2021.
  • Average Gross Profit over 5 years is $1.6 million, with a median of $2.0 million recorded in 2023.
  • The sharpest move saw Gross Profit surged 6157.61% in 2022, then grew 7.24% in 2025.
  • Year by year, Gross Profit stood at $23829.0 in 2021, then soared by 6157.61% to $1.5 million in 2022, then soared by 72.22% to $2.6 million in 2023, then grew by 20.44% to $3.1 million in 2024, then decreased by 0.63% to $3.1 million in 2025.
  • Business Quant data shows Gross Profit for SBFM at $3.1 million in Q3 2025, $3.4 million in Q2 2025, and $2.7 million in Q1 2025.